ONCOLOGY® Companion, Volume 36, Supplement 11

Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.

Experts from leading institutions debate the latest advances in multiple myeloma.

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.